| Initiated | Buy | X | ||
| Downgrades | Buy Hold | X | ||
|
$8 $4 |
||||
| Upgrades | Neutral Overweight | X | ||
|
$8 $10 |
||||
| Initiated | Buy | X | ||
| Initiated | Outperform | X | ||
| Initiated | Outperform | X | ||
| Initiated | Buy | X | ||
| Initiated | Overweight | X | ||
MIST Milestone Pharmaceuticals Inc.
Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker that has completed Phase II clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating atrial fibrillation and angina. The company was founded in 2003 and is headquartered in Montréal, Canada.
